SCHEMBL5213833

SCHEMBL5213833

O=C(O)c1coc(Cc2c(Cl)cccc2Cl)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.43
ALOX15 P16050 1/20 0.43
TSHR P16473 1/20 0.43
ACMSD Q8TDX5 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
AKR1B1 P15121 1/20 0.42
PTGER1 P34995 1/20 0.40
SLC22A12 Q96S37 1/20 0.38
CES1 P23141 1/20 0.37
MRGPRX4 Q96LA9 2/20 0.37
KLKB1 P03952 1/20 0.37
CCNA2 P20248 2/20 0.36
CDK2 P24941 2/20 0.36
CCNA1 P78396 2/20 0.36
CDK5 Q00535 2/20 0.36
CDK5R1 Q15078 2/20 0.36
RARG P13631 1/20 0.36
RORC P51449 1/20 0.36
LMNA P02545 1/20 0.36
AR P10275 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5219307 0.83 SLC6A2 (0.42) TSHRTDP1PTGER1CCNA2CDK2
SCHEMBL14422265 0.78 HDAC1 (0.43) TDP1LMNAMEN1KMT2A
SCHEMBL11910638 0.78 CES1 (0.50) KDM4EALOX15TSHRACMSDTDP1
SCHEMBL14422264 0.76 SMN1; SMN2 (0.47) KDM4ETDP1LMNA
SCHEMBL14422204 0.75 TRPV1 (0.46) RORCLMNA
SCHEMBL1811036 0.73 CES1 (0.38) KDM4EALOX15TSHRACMSDTDP1
SCHEMBL13685198 0.72 IGFBP3 (0.39) PTGER1CES1
SCHEMBL742811 0.71 CES1 (0.39) KDM4EALOX15TSHRACMSDTDP1
SCHEMBL1707161 0.71 LMNA (0.43) PTGER1CES1MRGPRX4KLKB1LMNA
SCHEMBL2868442 0.70 NOTUM (0.46) KDM4EALOX15TSHRACMSDTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7265138-B2 Vanilloid receptor ligands and their use in treatments AMGEN INC. (US) 2007-09-04 US disclosed
US-7265138-B2 Vanilloid receptor ligands and their use in treatments AMGEN INC. (US) 2007-09-04 US disclosed
US-7265138-B2 Vanilloid receptor ligands and their use in treatments AMGEN INC. (US) 2007-09-04 US disclosed
EP-1818333-A1 Vanilloid receptor ligands and their use in treatments Amgen Inc. (US) 2007-08-15 EP disclosed
EP-1818333-A1 Vanilloid receptor ligands and their use in treatments Amgen Inc. (US) 2007-08-15 EP disclosed
EP-1603905-A1 VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS AMGEN INC. (US) 2005-12-14 EP disclosed
WO-2004072068-A1 VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS AMGEN INC. (US) 2004-08-26 WO disclosed
US-20040157845-A1 Vanilloid receptor ligands and their use in treatments AMGEN INC. 2004-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040157845-A1 Vanilloid receptor ligands and their use in treatments TRPV1, TRPV2, TRPV3 KDM4E 4111/4885ALOX15 523/4885TSHR 640/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.